Cargando…
Characterization of transit rates in the large intestine of mice following treatment with a CGRP antibody, CGRP receptor antibody, and small molecule CGRP receptor antagonists
OBJECTIVE: To characterize the effects of blocking calcitonin gene‐related peptide (CGRP) activity in a mouse model of gastrointestinal transport. BACKGROUND: Migraine management using CGRP modulating therapies can cause constipation of varying frequency and severity. This variation might be due to...
Autores principales: | Johnson, Kirk W., Li, Xia, Huang, Xiaofang, Heinz, Beverly A., Yu, Jianliang, Li, Baolin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545683/ https://www.ncbi.nlm.nih.gov/pubmed/35822594 http://dx.doi.org/10.1111/head.14336 |
Ejemplares similares
-
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020) -
Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
por: Haanes, Kristian Agmund, et al.
Publicado: (2020) -
Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023) -
CGRP and CGRP receptors in human and rhesus monkey cerebellum
por: Eftekhari, S, et al.
Publicado: (2013) -
Lipidated Calcitonin Gene-Related Peptide (CGRP) Peptide Antagonists Retain CGRP Receptor Activity and Attenuate CGRP Action In Vivo
por: Jamaluddin, Aqfan, et al.
Publicado: (2022)